Figure 3From: Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors TNF-α release by JY/WT cells and BTZ-resistant variants JY/35BTZ and JY/100BTZ. Cells were activated for 24 hours with 10 ng/ml PMA and 750 ng/ml Ionomycin, in the absence or presence of the indicated concentration bortezomib. Results depicted are means ± SD of 3 separate experiments. ** p < 0.01, * p < 0.05.Back to article page